Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16474120 | 0.94 | STAT6 (0.39) | STAT6HTR2BPYGLCYP51A1 | |
| SCHEMBL1550608 | 0.93 | AR (0.40) | STAT6HTR2BRETKDRBACE1 | |
| SCHEMBL1550195 | 0.93 | ALOX15 (0.42) | STAT6PYGLCYP51A1 | |
| SCHEMBL1932624 | 0.93 | GRIN2D (0.35) | STAT6HTR2BRETKDRHTRA1 | |
| SCHEMBL19856859 | 0.93 | CYP51A1 (0.40) | STAT6HTR2BHTRA1PYGLCYP51A1 | |
| SCHEMBL1549976 | 0.93 | CYP51A1 (0.40) | STAT6HTR2BHTRA1PYGLCYP51A1 | |
| SCHEMBL1550050 | 0.93 | CYP51A1 (0.40) | STAT6HTR2BHTRA1PYGLCYP51A1 | |
| SCHEMBL1932171 | 0.92 | PDE4B (0.34) | STAT6RETKDRDHODHMAP3K5 | |
| SCHEMBL1549516 | 0.88 | CYP51A1 (0.43) | STAT6PYGLCYP51A1 | |
| SCHEMBL1550049 | 0.88 | DRD2 (0.37) | STAT6HTR2BHTRA1PYGLCYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | claimed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | claimed |
| JP-2011529082-A | — | — | 2011-12-01 | — | — | JP | claimed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | claimed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2312947-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450484-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2312947-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | STAT6 2179/4885HTR2B 114/4885RET 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.